ABIOMED Inc. (ABMD)

175.97
0.67 0.38
NASDAQ : Health Technology
Prev Close 175.30
Open 177.03
Day Low/High 175.30 / 177.91
52 Wk Low/High 155.02 / 427.70
Volume 568.90K
Avg Volume 637.20K
Exchange NASDAQ
Shares Outstanding 45.38M
Market Cap 8.01B
EPS 5.80
P/E Ratio 31.58
Div & Yield N.A. (N.A)

Latest News

Abiomed Second Quarter Fiscal 2020 Earnings And Conference Call Notification

Abiomed Second Quarter Fiscal 2020 Earnings And Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, October 31, 2019, the Company will release financial results for the second quarter of fiscal 2020.

MONDAY DEADLINE ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Abiomed, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

MONDAY DEADLINE ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Abiomed, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abiomed, Inc.

Impella Procedural Outcomes In Japan: Myocarditis (Graphic: Business Wire)

Impella Procedural Outcomes In Japan: Myocarditis (Graphic: Business Wire)

Abiomed (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, announces the 1,000th patient has been treated with the Impella heart pump in Japan.

(Photo: Business Wire)

(Photo: Business Wire)

Data presented today from the National Cardiogenic Shock Initiative Study (NCSI) on 250 consecutive AMI cardiogenic shock (AMICS) patients from 49 sites demonstrates 72% survival at discharge with 98% native heart recovery.

The Impella CP Heart Pump, Manufactured By Abiomed, Enables Heart Recovery. (Photo: Business Wire)

The Impella CP Heart Pump, Manufactured By Abiomed, Enables Heart Recovery. (Photo: Business Wire)

Abiomed (NASDAQ: ABMD) announces the results of PROTECT III, the ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against ABIOMED, Inc. (ABMD) And October 7 Deadline

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against ABIOMED, Inc. (ABMD) And October 7 Deadline

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against ABIOMED, Inc.

Highest Court In Germany Affirms Strength Of Abiomed's Patents

Highest Court In Germany Affirms Strength Of Abiomed's Patents

The highest court in Germany, the Federal Court of Justice, recently ruled in favor of Abiomed (NASDAQ: ABMD) in a patent challenge filed by Thoratec in 2015 and validated the strengths of Abiomed's Impella-related patents.

Abiomed Will Showcase Technological Innovations At TCT 2019, Including Impella CP® With SmartAssist™, Which Is Designed To Improve Outcomes By Using Real-time Intelligence To Optimize Positioning, Managing And Weaning Of The Impella Device For Better Patient Care. (Graphic: Business Wire)

Abiomed Will Showcase Technological Innovations At TCT 2019, Including Impella CP® With SmartAssist™, Which Is Designed To Improve Outcomes By Using Real-time Intelligence To Optimize Positioning, Managing And Weaning Of The Impella Device For Better Patient Care. (Graphic: Business Wire)

Abiomed (NASDAQ:ABMD) will highlight the benefits of complete revascularization with Protected PCI and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients at the 31 st Transcatheter...

Abiomed To Present At The Morgan Stanley Global Healthcare Conference

Abiomed To Present At The Morgan Stanley Global Healthcare Conference

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In ABIOMED, Inc. Of Class Action Lawsuit And Upcoming Deadline - ABMD

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In ABIOMED, Inc. Of Class Action Lawsuit And Upcoming Deadline - ABMD

NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ABIOMED, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: None Downgrades: ABMD, ATI, BWA, CRM, IFF, LBRT, NBEV, SFIX, VIA Initiations: BJ, EVSI, ONE Read on to get TheStreet Quant Ratings' detailed report:

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Abiomed, Inc. Investors Of Important Deadline In Securities Class Action - ABMD

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Abiomed, Inc. Investors Of Important Deadline In Securities Class Action - ABMD

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abiomed, Inc.

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Abiomed, Inc.

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Abiomed, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming October 7, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Abiomed, Inc.

ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Abiomed, Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - ABMD

ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Abiomed, Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - ABMD

NEW YORK, Aug. 9, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Abiomed, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Abiomed, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Abiomed, Inc. To Contact The Firm

NEW YORK, Aug. 8, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abiomed, Inc.

Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Abiomed, Inc. Investors (ABMD)

Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Abiomed, Inc. Investors (ABMD)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Abiomed, Inc.

Shareholder Alert: Robbins Arroyo LLP Announces Abiomed, Inc. (ABMD) Sued For Misleading Shareholders

Shareholder Alert: Robbins Arroyo LLP Announces Abiomed, Inc. (ABMD) Sued For Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Abiomed, Inc.

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Abiomed, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Abiomed, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc.

ABMD SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Abiomed Inc.

ABMD SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Abiomed Inc.

NEW YORK, Aug. 7, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of shareholders of  Abiomed, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Abiomed, Inc. - ABMD

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Abiomed, Inc. - ABMD

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Abiomed, Inc.

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Abiomed, Inc. (ABMD)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Abiomed, Inc. (ABMD)

NEW YORK, Aug. 6, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abiomed, Inc.

Abiomed Slumps After Revising Fiscal 2020 Revenue Estimate Lower

Abiomed Slumps After Revising Fiscal 2020 Revenue Estimate Lower

New training programs, organizational changes in distribution, and certain external initiatives implemented in the first quarter 'will require time to drive more growth,' the CEO says.

Ambiomed Stock: A Look Forward

Ambiomed Stock: A Look Forward

ABMD has been one of the best-performing stocks in the S&P 500 over the past five years.

Abiomed First Quarter Fiscal 2020 Earnings And Conference Call Notification

Abiomed First Quarter Fiscal 2020 Earnings And Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 1, 2019, the Company will release financial results for the first quarter of fiscal 2020.

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.

The Impella Heart Pump Helped Iman Dorty's Heart Recover So She Could Return Home To Her Family. (Photo: Abiomed, Inc.)

The Impella Heart Pump Helped Iman Dorty's Heart Recover So She Could Return Home To Her Family. (Photo: Abiomed, Inc.)

Abiomed's (NASDAQ:ABMD) Impella platform is being featured today at a Washington, D.

TheStreet Quant Rating: C+ (Hold)